IMDELLTRA® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. …READ MORE
IMDELLTRA® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
You are now leaving IMDELLTRAhcp.com and entering another Amgen website. Amgen is not adopting such content into this website.
You are now leaving IMDELLTRAhcp.com and entering another external website. Amgen is not responsible for the content of the third party website and is not adopting such content into this website.